FDA to consider drug affordability when speeding up approvals: Makary
The agency’s commissioner Marty Makary told the CNBC on Friday, the food and pharmaceutical administration will consider the purchase of drugs while giving companies to new coupons that accelerate the approval of some treatments.
In June, the FDA announced a national priority coupon plan aimed at reduce drug investigation times to one to two months for companies he said he supports “US national interests”. But the previous announcements In the coupon program, he did not explicitly mention the making of drugs more affordable as a criterion.
Makary, in his statement to CNBC, “We add theability of drugs as a national priority.” He said.
It is a fundamental goal of the Trump administration, which is facing a challenging act of balancing because it threatens to apply up to 200% of drugs imported to the United States to revitalize drug production and to revitalize drug production.
Marty Makary, a commissioner of the Food and Pharmaceutical Administration, speaks at a press conference on the removal of synthetic paints from the food supply of the US in the health and human services center in Washington, DC on 22 April 2025.
Nathan Posner | Anatolia | Getty Images
Makary, President Donald Trump “is very determined to reduce drug prices for Americans, and Americans in the United States in the United States compared to other developed countries two, five, 10 times higher drugs higher,” he added, he added.
However, it is unclear how the Trump administration will consider how to be met when examining a drug, because the launch of a product is usually determined after a approval in the USA
FDAs website Currently, it summarizes four “national priorities” to determine which companies will receive a coupon under the new program. This includes addressing a health crisis in the United States, offering “more innovative treatments” to the Americans, to address the uncomfortable public health needs, and to “increase domestic drug production as a national security problem”.
According to a Wall Street Journal, drugs may be included in the previously included report In June.
The spokesman of the Department of Health and Human Services confirmed that the FDA will take into account the purchase of drugs for the program, and the addition of criteria is not limited to previous examples.
When companies are asked to give examples of a health crisis where they can meet their drugs, a treatment for type 1 diabetes, more treatment for neurodegenerative diseases and a universal flu shot “So there is no need to guess which species are coming.”
He also said he wanted to get more treatment for stage 4 cancer or when the disease spreads from the original region to the distant parts of the body.
“We have a committee to determine which products and companies will take these coupons as part of the pilot.” He said. “But we should try new things. We have to ask ourselves, why it takes so long to come to the market? And we want to see more treatment and meaningful treatments for the Americans.”
FDA will give new coupons this year. After one year of pilot, the agency can increase the number of rapid approval it is given to companies.
Some Wall Street analysts said that the coupon program may be more effective than tariffs in encouraging drug producers to bring their production to the United States.
However, questions about the risks of accelerating drugs up to 30 days, which is the fastest thing that the FDA has ever done.
Another potential concern is whether the FDA will present coupons to the political allies of Trump administration; This may include companies that the agency staff normally examine.
